Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese

Clinical Neurology and Neurosurgery

Volumn 113, Issue 8, 2011, Pages 617-622

  Chan, K H ^a,b   Tsang, K L ^a   Ho, P W L ^a   Tse, C T ^a   Kwan, J S C ^a   Ho, J W M ^a   Chu, A C Y ^a   Chang, R S K ^a   Ho, S L ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Interferon; Expanded disability status scale score; Hong Kong Chinese; Relapsing remitting multiple sclerosis; Secondary progression multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; METHOTREXATE; MITOXANTRONE; NATALIZUMAB;

ARTICLE; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEURORADIOLOGY; ONSET AGE; OUTCOME ASSESSMENT; RELAPSE; RETROSPECTIVE STUDY; SEROLOGY; SIDE EFFECT;

ADOLESCENT; ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; BRAIN; CHILD; FEMALE; FOLLOW-UP STUDIES; HONG KONG; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; SPINAL CORD; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052183109     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2011.04.013     Document Type: Article

References (52)

1. J.H. Noseworthy, C.F. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis N Eng J Med 343 2000 938 952
2. L. Steinman Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system Cell 85 1996 299 302 (Pubitemid 26160700)
3. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
4. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 1993 655 661
5. D.S. Goodin, E.M. Frohman, G.P. Garmany, J. Halper, W.H. Likosky, and F.D. Lublin Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 2002 169 178 (Pubitemid 34086933)
6. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, and A.M. Salazar Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann Neurol 39 1996 285 294 (Pubitemid 26100751)
7. E.M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, and M.K. Sharief Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis Arch Neurol 63 2006 614 617
8. S.J. Pittock, B.G. Weinshenker, J.H. Noseworthy, C.F. Lucchinetti, M. Keegan, and D.M. Wingerchuk Not every patient with multiple sclerosis should be treated at time of diagnosis Arch Neurol 63 2006 611 614
9. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann Neurol 58 2005 840 846 (Pubitemid 41746873)
10. D.M. Wingerchuk, V.A. Lennon, S.J. Pittock, C.F. Lucchinetti, and B.G. Weinshenker Revised diagnostic criteria for neuromyelitis optica Neurology 66 2006 1485 1489 (Pubitemid 43958540)
11. B.G. Weinshenker, P.C. O'Brien, T.M. Patterson, J.H. Noseworthy, C.F. Lucchinetti, and D. Dodick A randomized trial of plasma exchange in acute central nervous system inflammatory disease Ann Neurol 46 6 1999 878 886
12. D. McAlpine, and N. Compston Some aspects of the natural history of disseminated sclerosis QJM 82 1952 135 167
13. J.F. Kurtzke, G.W. Beebe, B. Nagler, L.T. Kurland, and T.L. Auth Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness J Chron Dis 30 1977 819 830 http://www.ncbi.nlm. nih.gov/pubmed?term=%22Kurland%20LT%22%5BAuthor%5D, http://www.ncbi.nlm.nih.gov/ pubmed?term=%22Auth%20TL%22%5BAuthor%5D (Pubitemid 8242208)
14. S. Poser, H.J. Bauer, and W. Poser Prognosis of multiple sclerosis results from an epidemiological area in Germany Acta Neurol Scand 65 1982 347 354 (Pubitemid 12074145)
15. C. Confavreux, G. Aimard, and M. Devic Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients Brain 103 1980 281 300 (Pubitemid 10046624)
16. R. Detel, V.A. Clark, N.L. Valdiviezo, B.R. Visscher, R.M. Malmgren, and J.P. Dudley Factors associated with a rapid course of multiple sclerosis Arch Neurol 39 1982 337 341 (Pubitemid 12109203)
17. B.R. Visscher, K.S. Liu, V.A. Clark, R. Detels, R.M. Malmgren, and J.P. Dudley Onset symptoms as predictors of mortality and disability in multiple sclerosis Acta Neurol Scand 70 1984 321 328 (Pubitemid 14012701)
18. S.J. Pittock, R.L. McClelland, W.T. Mayr, N.W. Jorgensen, B.G. Weinshenker, and J. Noseworthy Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study Ann Neurol 56 2004 303 306 (Pubitemid 39037929)
19. B.G. Weinshenker, G.P. Rice, J.H. Noseworthy, W. Carriere, J. Baskerville, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome Brain 114 2 1991 1045 1056
20. L.D. Jacobs, R.W. Beck, J.H. Simon, R.P. Kinkel, C.M. Brownscheidle, and T.J. Murray Intramuscular interferon beta-1a therapy during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Eng J Med 343 2000 898 904
21. G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, and O. Fernandez Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study Lancet 357 2001 1576 1582 (Pubitemid 32488815)
22. Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis (PRISMS) study group. Randomized double-blinded placebo-controlled study of interferon beta 1a in relapsing/remitting multiple sclerosis Lancet 352 1998 1498 1504
23. P. Rieckmann, K.V. Toyka, C. Bassetti, K. Beer, S. Beer, and U. Buettner Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis - new aspects and practical application J Neurol 251 2004 1329 1339
24. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, and J. Baskerville The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 112 1989 133 146 (Pubitemid 19056478)
25. L. Kappos, C.H. Polman, M.S. Freeman, G. Edan, H.P. Hartung, and D.H. Miller Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249 (Pubitemid 44563835)
26. C.H. Polman, L. Kapps, M.S. Freedman, G. Edan, H.P. Hartung, D.H. Miller for the BENEFIT Study Group Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Subgroup Analyses Neurology 66 Suppl 2 2006 A61
27. R.P. Kinkel, C. Kollman, P. O'Connor, T.J. Murray, J. Simon, and D. Arnold IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event Neurology 66 2006 678 684 (Pubitemid 43739821)
28. M. Filippi, M. Rovaris, M. Inglese, F. Barkhof, N. De Stefano, and S. Smith Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo controlled trial Lancet 364 2004 1463 1464
29. M. Trojano, F. Pellegrini, A.F. MscStat, D. Paolicelli, V. Zipoli, and G.B. Zimatore New natural history of interferon-β-treated relapsing multiple sclerosis Ann Neurol 61 2007 300 306 (Pubitemid 46676729)
30. K.H. Chan, K.L. Tsang, C.Y. Fong, S.L. Ho, R.T.F. Cheung, and W. Mak Idiopathic inflammatory demyelinating disorders after acute transverse myelitis Eur J Neuro 13 2006 862 868 (Pubitemid 44124683)
31. J. Palace, and P. Rothwell New treatments and azathioprine in multiple sclerosis Lancet 350 1997 261 [letter] (Pubitemid 27312298)
32. S.J. Pittock, W.T. Mayr, R.L. McClelland, N.W. Jorgensen, S.D. Wegand, and J.H. Noseworthy Change in MS-related disability in a population-based cohort: a 10-year follow-up study Neurology 62 2004 51 59 (Pubitemid 38082870)
33. H. Tremlett, D. Paty, and V. Devonshire Disability progression in multiple sclerosis is slower than previously reported Neurology 66 2006 172 177 (Pubitemid 43970148)
34. S. Vukusic, and C. Confavreux Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis J Neurol Sci 206 2003 135 137 (Pubitemid 36143717)
35. S. Vukusic, and C. Confavreux Natural history of multiple sclerosis: risk factors and prognostic indicators Curr Opin Neurol 20 2007 269 274 (Pubitemid 46743107)
36. C. Confavreux, and S. Vukusic Age at disability milestones in multiple sclerosis Brain 129 2006 595 605 (Pubitemid 43278222)
37. K.H. Chan, D.B. Ramsden, Y.L. Yu, K.H.H. Kwok, A.C.Y. Chu, and P.W.L. Ho NMO-IgG in idiopathic inflammatory demyelinating disorders among Hong Kong Chinese Eur J Neuro 16 2009 310 316
38. K.K. Lau, W.W.Y. Wong, B. Sheung, I.T.S. Yu, B.H. Fung, and H.L. Li The clinical course of multiple sclerosis patients in Hong Kong J Neurol Sci 268 2008 78 82
39. G. Filippini, L. Munari, B. Incorvaia, G.C. Ebers, C. Polman, and R. D'Amico Interferons in relapsing remitting multiple sclerosis: a systematic review Lancet 361 2003 545 552 (Pubitemid 36207471)
40. L. Kappos, M.S. Freedman, C.H. Polman, G. Edan, H.P. Hartung, D.H. Miller for the BENEFIT Study Group Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Lancet 370 2007 389 397 (Pubitemid 47189673)
41. D.M. Wingerchuk, W.F. Hogancamp, P.C. O'Brien, and B.G. Weinshenker The clinical course of neuromyelitis optica (Devic's syndrome) Neurology 53 1999 1107 1114 (Pubitemid 29442132)
42. L. Kappos, M.S. Freedman, C.H. Polman, G. Edan, H.P. Hartung, and D.H. Miller Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Lancet Neurol 8 2009 987 997
43. T.P. Hung, D. Landsborough, and M.S. Hsi Multiple sclerosis amongst Chinese in Taiwan J Neurol Sci 27 1976 469 484
44. Y.L. Yu, E. Woo, B.R. Hawkins, H.C. Ho, and C.Y. Huang Multiple sclerosis amongst Chinese in Hong Kong Brain 112 1989 1445 1467 (Pubitemid 20024214)
45. C.P. Tsai, C.L. Yuan, H.Y. Yu, C. Chen, Y.C. Guo, and D.E. Shan Multiple sclerosis in Taiwan J Chin Med Assoc 67 2004 500 505 (Pubitemid 40069082)
46. Q. Cheng, L. Miao, J. Zhang, S.J. Ding, Z.G. Liu, and X. Wang A population-based survey of multiple sclerosis in Shanghai China. Neurology 68 2007 1495 1500 (Pubitemid 46685920)
47. Q. Cheng, X.J. Cheng, and G.X. Jiang Multiple sclerosis in China - history and future Mult Scler 15 2009 655 660
48. K.H. Chang, R.K. Lyu, C.M. Chen, W.C. Hsu, Y.R. Wu, and S.T. Chen Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study Mult Scler 12 2006 501 506
49. G.S.M. Ramsaransing, and J. De Keyser Benign course in multiple sclerosis: a review Acta Neurol Scand 113 2006 359 369 (Pubitemid 44046321)
50. B.G. Weinshenker, D.M. Wingerchuk, I. Nakashima, K. Fujihara, and V.A. Lennon OSMS is NMO, but not MS: proven clinically and pathologically Lancet Neurol 5 2006 110 111 (Pubitemid 43107844)
51. G. Rosati The prevalence of multiple sclerosis in the world: an update Neurol Sci 22 2001 117 139 (Pubitemid 33771279)
52. J. Benedikz, M. Stefansson, J. Guomundsson, A. Jonasdottir, R. Fossdai, and J. Gulcher The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study Clin Neuro Neurosurg 104 2002 208 210 (Pubitemid 34799912)